Immunity Chap 5
... surface in combination with the MHC (Major Histocompatibility complex) II complex Antigen is presented to a specific helper T cell that has receptors that match the antigen – MHC II complex ...
... surface in combination with the MHC (Major Histocompatibility complex) II complex Antigen is presented to a specific helper T cell that has receptors that match the antigen – MHC II complex ...
Lecture-6-ANTIBODY-STRUCTURE-AND
... Fc receptors also mediate Antibody-Dependent Cellular Cytotoxicity (ADCC) Natural Killer Cells ...
... Fc receptors also mediate Antibody-Dependent Cellular Cytotoxicity (ADCC) Natural Killer Cells ...
ppt lecture
... successful in chronic myeloid leukemia and in gastrointestinal stromal tumors. It is being tested in other types of cancer. ...
... successful in chronic myeloid leukemia and in gastrointestinal stromal tumors. It is being tested in other types of cancer. ...
Immune System
... Insoluble Ant/Ab deposit in the microvasculature Ca /neutrophils---tissue damage ...
... Insoluble Ant/Ab deposit in the microvasculature Ca /neutrophils---tissue damage ...
Exporter la page en pdf
... We have discovered that an innate immune response to HIV-1 exists in dendritic cells. HIV-1 is normally unable to infect dendritic cells and we have used the Vpx protein found in other lentiviruses to render dendritic cells susceptible to HIV-1 infection. In these conditions, infection of dendritic ...
... We have discovered that an innate immune response to HIV-1 exists in dendritic cells. HIV-1 is normally unable to infect dendritic cells and we have used the Vpx protein found in other lentiviruses to render dendritic cells susceptible to HIV-1 infection. In these conditions, infection of dendritic ...
Pathogenic Mechanisms of Uveitis
... The two components of the anterior uvea, the iris and the ciliary body, contain heavily pigmented connective, vascular, and muscle tissue. The iris functions as a shutter that responds to prevailing light conditions, and the ciliary body produces aqueous humor through active secretion and ultrafiltr ...
... The two components of the anterior uvea, the iris and the ciliary body, contain heavily pigmented connective, vascular, and muscle tissue. The iris functions as a shutter that responds to prevailing light conditions, and the ciliary body produces aqueous humor through active secretion and ultrafiltr ...
Document
... -B2 widely distributed in lymphoid organs and tissues. -IgM and IgD present on both cells surface. -Isotype switching is typical for B2 lineage. -Markers : CD19, and CD20. ...
... -B2 widely distributed in lymphoid organs and tissues. -IgM and IgD present on both cells surface. -Isotype switching is typical for B2 lineage. -Markers : CD19, and CD20. ...
Presentation
... recognition of dsRNA in cytoplasm and inhibits virus replication (also promotes adaptive immunity) •Killing of infected cells is also performed by natural killer cells recognizing stress-induced molecules or loss of MHC class I molecule expression and by cytotoxic T cells which recognize virus antig ...
... recognition of dsRNA in cytoplasm and inhibits virus replication (also promotes adaptive immunity) •Killing of infected cells is also performed by natural killer cells recognizing stress-induced molecules or loss of MHC class I molecule expression and by cytotoxic T cells which recognize virus antig ...
The Immune System
... • Known to increase in number in the event of parasitic worm infection and during allergic reaction. ...
... • Known to increase in number in the event of parasitic worm infection and during allergic reaction. ...
Immunology powerpoint
... agglutination or clotting) IgG: major type of antibody secreted during a secondary immune response IgE: type most associated with allergic reactions (promotes release of histamine) ...
... agglutination or clotting) IgG: major type of antibody secreted during a secondary immune response IgE: type most associated with allergic reactions (promotes release of histamine) ...
Marginal zone B cells
... 1. For cytotoxic CD8 T-cells, ligation of the TCR by MHC I/peptide + co-stimulation results in release of granzymes and perforin and/or FasL, leading to apoptosis of the target cells. 2. Viruses evade host defense, in part, by down-regulating MHC Class I. Uninfected dendritic cells circumvent this b ...
... 1. For cytotoxic CD8 T-cells, ligation of the TCR by MHC I/peptide + co-stimulation results in release of granzymes and perforin and/or FasL, leading to apoptosis of the target cells. 2. Viruses evade host defense, in part, by down-regulating MHC Class I. Uninfected dendritic cells circumvent this b ...
File
... combination of cell surface proteins that are specific to that person. This is the person’s “antigen signature” The “antigen signature” is critical to ensure that a person’s own lymphocytes do not try to destroy their own body cells surface proteins. This normally does not happen because during matu ...
... combination of cell surface proteins that are specific to that person. This is the person’s “antigen signature” The “antigen signature” is critical to ensure that a person’s own lymphocytes do not try to destroy their own body cells surface proteins. This normally does not happen because during matu ...
antibody
... A number of anti tumour agents including chlorambucil, methotrexate, Daunomycin and Doxorubicin conjugated to tumour specific antibodies. Eg: Doxorubicin-BR96 immunoconjugate. It is a chimeric MoAb specific for lewis antigen found on the surface of tumour cells. CMA-676 which is a conjugate of a ...
... A number of anti tumour agents including chlorambucil, methotrexate, Daunomycin and Doxorubicin conjugated to tumour specific antibodies. Eg: Doxorubicin-BR96 immunoconjugate. It is a chimeric MoAb specific for lewis antigen found on the surface of tumour cells. CMA-676 which is a conjugate of a ...
THE IMMUNE RESPONSE AGAINST INTRACELLULAR BACTERIA
... They encase the infected cells in a “cage” of “extracellular matrix” proteins where they can stay for years! ...
... They encase the infected cells in a “cage” of “extracellular matrix” proteins where they can stay for years! ...
Targeted therapy in renal cell carcinoma: moving from molecular
... Adoptive T-cell transfer represents another, considerably successful strategy in tumor immunotherapy. It is known that often tumor-infiltrating lymphocytes (TIL) are present within the RCC tumor tissue [4]. The presence of TILs suggests that the patient’s immune system has been activated to fight th ...
... Adoptive T-cell transfer represents another, considerably successful strategy in tumor immunotherapy. It is known that often tumor-infiltrating lymphocytes (TIL) are present within the RCC tumor tissue [4]. The presence of TILs suggests that the patient’s immune system has been activated to fight th ...
02-04-12 ALLERGY: • META-ANALYSIS OF CLINICAL TRIALS ON
... Human basophils cannot be activated through IgG receptors (their functions are inhibited by IgG-mediated triggering via FcyRIIb receptors). ...
... Human basophils cannot be activated through IgG receptors (their functions are inhibited by IgG-mediated triggering via FcyRIIb receptors). ...
Document
... pathogenic. To fight infection quickly the intestine has several innate immune defences designed to act immediately when alerted to danger. ...
... pathogenic. To fight infection quickly the intestine has several innate immune defences designed to act immediately when alerted to danger. ...
Theories of Autoimmunity
... - a synthetic peptide is used to bind in place of the regular peptide on the MHC - induces a state of clonal anergy in the autoimmune T-cells ...
... - a synthetic peptide is used to bind in place of the regular peptide on the MHC - induces a state of clonal anergy in the autoimmune T-cells ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.